- Education
- Source: Campus Sanofi
- 1 Jun 2024
EBMT 2024: Expanding the cGvHD treatment paradigm with novel therapeutics
Rezurock▼ (Belumosudil) is intended for HCPs practising in Great Britain (England, Scotland and Wales) only.
Expanding the treatment paradigm with novel therapeutics
Length: 10mins
This video introduces novel therapies for chronic GvHD treatment, an overview of the MOAs, and an overiew of the key data from complete clinical trials.
More educational content
Advances in the biology of chronic GvHD
Frontline treatment of chronic GvHD
Treatment of steroid refractory chronic GvHD
QoL and chronic GvHD
Roundtable discussion: Exploring clinical cases
Expert exchange: Exploring the clinical practicalities of managing GvHD
The late effects of chronic GvHD: The challenge of long-term management
Pulmonary chronic GvHD: The need for early identification and improved management
More educational content
Advances in the biology of chronic GvHD
Frontline treatment of chronic GvHD
Treatment of steroid refractory chronic GvHD
QoL and chronic GvHD
Roundtable discussion: Exploring clinical cases
Expert exchange: Exploring the clinical practicalities of managing GvHD
The late effects of chronic GvHD: The challenge of long-term management
Pulmonary chronic GvHD: The need for early identification and improved management
Explore more on Campus
Get the latest updates about REZUROCK
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
ROCKstar Study
Download ROCKstar study summary. This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Explore more on Campus
Get the latest updates about REZUROCK
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
ROCKstar Study
Download ROCKstar study summary. This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
cGvHD - chronic Graft versus Host Disease
MAT-XU-2402250 (v1.0) Date of Preparation: August 2024